Rift Genomics · MRD monitoring solution

Track every clone,at every timepoint.

NGS immunosequencing kit and clone-tracking software for measurable residual disease in multiple myeloma, B-ALL and T-ALL.

RUOResearch Use Only

BCR + TCR
Myeloma, B-ALL and T-ALL on two panels, one workflow
Kit + software
Library-prep kit and clone tracking, supplied together
In-house
Bring sequencing and interpretation together in your laboratory
Every timepoint
From diagnosis through maintenance and after CAR-T

Clinical need

MRD is now part of standard care.

The latest myeloma and ALL guidelines make MRD a routine, repeated measurement. Laboratories need to run it in-house, at depth, at every timepoint.

Multiple myeloma · NCCN, September 2026

Multiple myeloma

  • Dedicated MRD testing page in the guideline
  • Bone marrow MRD by NGS or flow cytometry
  • Sensitivity of 10⁻⁵ minimum, 10⁻⁶ preferred
  • Test after treatment, yearly during maintenance and after CAR-T
  • New IMS/IMWG cure definition: at least four negative MRD tests at 10⁻⁶ over five years

Acute lymphoblastic leukaemia · NCCN

Acute lymphoblastic leukaemia

  • MRD at end of induction and at later timepoints
  • Sensitivity of at least 10⁻⁴; NGS can reach 10⁻⁶
  • Both B-ALL and T-ALL must be covered

What the sensitivity levels mean

10⁻⁴1 in 10,000 cells
10⁻⁵1 in 100,000 cells
10⁻⁶1 in 1,000,000 cells

Guideline points summarised from NCCN Guidelines for Multiple Myeloma (September 2026) and Acute Lymphoblastic Leukaemia, and the IMS/IMWG cure definition (September 2026). Always refer to the current guideline version.

Coverage

DiseaseCell of originReceptor genes trackedRift panel
Multiple myelomaB cellIGH, IGK, IGLBCR panel
B-ALLB cellIGH, IGK, IGLBCR panel
T-ALLT cellTCR beta, gamma, alpha, deltaTCR panel

Why NGS-based MRD

One panel for every patient. A sequence-level answer.

Each patient’s clones are identified from the diagnostic sample, then followed by their exact CDR3 sequence at every later timepoint.

No patient-specific assay design

The same panel runs for every patient. Each patient’s clones are identified from the diagnostic sample.

Several clones at once

Heavy and light chains are tracked together, so clonal evolution is less likely to be missed.

Sequence-level result

Each clone is identified by its exact CDR3 sequence, giving a digital, reproducible readout.

The kit

Immunosequencing built for rare clones.

Two targeted NGS panels, one for B-cell receptors and one for T-cell receptors, share a single adapter-anchored targeted PCR workflow.

CDR3 = clone fingerprint Adapter UMI V (D)J Constant region Adapter primer Gene-specific primer Every moleculebarcoded

One primer sits in the conserved constant region; the other end is the ligated adapter. No primer has to bind the hypervariable V(D)J sequence.

Reads through hypervariable regions

Primers bind the conserved constant region, so V(D)J diversity and variable fragment lengths do not cause drop-outs.

Molecular barcodes

A unique tag on every input molecule lets the software collapse PCR copies and discard sequencing errors.

Nested PCR

A second gene-specific primer adds specificity, so low-level clones stand out from background.

From sample to MRD status

  1. SampleBone marrow, blood or tissue
  2. RNAExtract total RNA
  3. LibraryRift kit1.5 days
  4. SequenceIllumina
  5. TrackRift MRD software
  6. ReportMRD status per timepoint
Rift BCR panelRift TCR panel
TargetsIGH heavy chain plus kappa and lambda light chains, with isotype callingTCR beta, gamma, alpha and delta chains
ApplicationsMRD tracking, clonality, hypermutation status, repertoire studiesMRD tracking, clonality, repertoire and T-cell infiltration studies
Input20 ng – 6 µg total RNA20 ng – 2 µg total RNA
Sample typesBone marrow, blood, PBMC, sorted B cells, FFPE, fresh frozenBlood, PBMC, sorted T cells, FFPE, fresh frozen
SequencingIllumina · 250K – 10M reads per sampleIllumina · 250K – 10M reads per sample
Hands-on time3.5 hours3.5 hours
Library prep1.5 days1.5 days
FormatFreeze-dried reagents, one tube per reactionFreeze-dried reagents, one tube per reaction

How much RNA and how many reads you need depends on the sample and on the depth of MRD testing required.

The software

From reads to MRD status, per patient.

Rift MRD software links every sample to its patient, finds the index clones at diagnosis and tracks them at every later timepoint.

Rift MRD · Patient 0427 · Multiple myeloma · IGH + IGK

Index clone frequency over time

1e−21e−31e−41e−51e−6 DxEOIC1ASCTM1

Tracked clones

CloneLocusCDR3DxLatest
C1IGHCARDGYSSGWYFDYW41.2%neg.
C2IGKCQQYNSYPLTF38.7%neg.
C3IGHCAKDRGYCSGGSCYW0.9%neg.
C4IGLCQSYDSSLSGSVF0.3%neg.

Status at M1: MRD-negative · 4 index clones tracked

Explore example data.

Index clone detection

Identifies each patient’s malignant clonotypes from the diagnostic sample.

Longitudinal tracking

Follows the same clones across every follow-up sample, from induction to maintenance.

Error-corrected counts

Uses molecular barcodes to remove PCR duplicates and sequencing errors before counting.

MRD timeline

Shows clone frequency and MRD status at each timepoint, against guideline thresholds.

Ready-to-sign reports

Generates a per-patient MRD report for review and sign-off by your team.

Local or on-premise

Runs on your own servers, so patient data stays inside your institution.

One supplier, from kit to report

Everything you need to get running.

  • Kit supply and logistics
  • Software installation and training
  • Implementation and validation support
  • Ongoing scientific and technical support

RUOFor Research Use Only. Not for use in diagnostic procedures.

Bring MRD testing
in-house.

See the kit and software in a demonstration, or talk to us about implementation and validation.